BioNexus Gene Lab Corp. (BGLC)

OTCMKTS: BGLC · Delayed Price · USD

0.849

+0.190 (28.77%)

Apr 18, 2024, 4:00 PM EDT - Market closed

BioNexus Gene Lab Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	9.77	10.93	13.36	11.39	0.13	0.21
Revenue Growth (YoY)	-10.60%	-18.21%	17.31%	8872.03%	-40.21%	-
Cost of Revenue	8.44	9.67	11.17	9.67	0.07	0.18
Gross Profit	1.33	1.26	2.19	1.72	0.06	0.03
Selling, General & Admin	4.41	1.73	1.2	1.33	0.36	0.24
Other Operating Expenses	0	-0.18	-0.07	-0.89	-0.03	0.27
Operating Expenses	4.41	1.55	1.14	0.45	0.33	-0.03
Operating Income	-2.59	-0.29	1.06	1.27	-0.28	0.06
Interest Income	0	0.01	0.01	0.01	0	0
Interest Expense	0	0.01	0.01	0.01	0	0
Other Expense / Income	0.04	0.01	0.01	0.01	-	-
Pretax Income	-2.63	-0.3	1.04	1.26	-0.28	0.06
Income Tax	0	0.05	0.29	0.17	-0.03	0.03
Net Income	-2.63	-0.36	0.75	1.09	-0.25	0.03
Net Income Growth	-	-	-31.31%	-	-	-
Shares Outstanding (Basic)	16	14	14	9	7	6
Shares Outstanding (Diluted)	16	14	14	9	7	6
Shares Change	10.17%	0.99%	66.36%	19.16%	30.20%	-
EPS (Basic)	-0.17	-0.02	0.05	0.13	-0.03	0.00
EPS (Diluted)	-0.17	-0.02	0.05	0.13	-0.03	0.00
EPS Growth	-	-	-59.46%	-	-	-
Free Cash Flow	-1.3	0.49	0.01	0.13	-0.23	-0.31
Free Cash Flow Per Share	-0.08	0.03	0.00	0.02	-0.03	-0.06
Gross Margin	13.61%	11.52%	16.42%	15.10%	44.02%	13.55%
Operating Margin	-26.54%	-2.66%	7.90%	11.18%	-217.17%	28.21%
Profit Margin	-26.91%	-3.26%	5.62%	9.61%	-194.14%	12.46%
Free Cash Flow Margin	-13.32%	4.48%	0.04%	1.15%	-181.24%	-147.74%
Effective Tax Rate	-	-	27.93%	13.34%	-	55.84%
EBITDA	-2.59	-0.19	1.16	1.38	-0.22	0.1
EBITDA Margin	-26.54%	-1.70%	8.71%	12.08%	-175.16%	47.34%
Depreciation & Amortization	0.03	0.11	0.11	0.1	0.05	0.04
EBIT	-2.62	-0.29	1.06	1.27	-0.28	0.06
EBIT Margin	-26.80%	-2.66%	7.90%	11.18%	-217.17%	28.21%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.